{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:50:34Z","timestamp":1761767434439,"version":"3.40.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016838","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016838","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jacadv.2025.101665","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T06:39:51Z","timestamp":1742539191000},"page":"101665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Apixaban Dose in Patients With Atrial\u00a0Fibrillation and Acute Coronary Syndrome and\/or Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"4","author":[{"given":"Marat","family":"Fudim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jacadv.2025.101665_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101665_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101665_bib3","first-page":"51","article-title":"Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome?","volume":"17","author":"Menditto","year":"2020","journal-title":"J\u00a0Geriatr Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101665_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.amjcard.2017.12.003","article-title":"Influence of atrial fibrillation on outcomes in patients who underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"121","author":"Garg","year":"2018","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101665_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1536\/ihj.16-286","article-title":"Atrial fibrillation on admission is related with higher mortality in ST-segment elevation myocardial infarction patients","volume":"58","author":"Hwang","year":"2017","journal-title":"Int Heart J"},{"key":"10.1016\/j.jacadv.2025.101665_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.advms.2017.06.005","article-title":"Patients with atrial fibrillation and coronary artery disease\u2014 double trouble","volume":"63","author":"Michniewicz","year":"2018","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.jacadv.2025.101665_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.jacadv.2025.101665_bib8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101665_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rth2.12319","article-title":"Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention\/stenting","volume":"4","author":"Kozie\u0142","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jacadv.2025.101665_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101665_bib11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jacadv.2025.101665_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101665_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","article-title":"Apixaban 5\u00a0mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine","volume":"1","author":"Alexander","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2025.101665_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical in investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101665_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"10","key":"10.1016\/j.jacadv.2025.101665_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2025.101665_bib17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101665_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101665_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25000821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25000821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T06:35:13Z","timestamp":1745476513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25000821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2772963X25000821"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101665","relation":{},"ISSN":["2772-963X"],"issn-type":[{"type":"print","value":"2772-963X"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban Dose in Patients With Atrial\u00a0Fibrillation and Acute Coronary Syndrome and\/or Undergoing Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101665"}}